Search Results for “Alzheimer” – Page 6 – media

Alzheimer’s Association report highlights need to improve patient-physician communication Both individuals and primary care physicians reported a reluctance to address cognitive concerns

A new report from the Alzheimer’s Association has highlighted a need to improve patient-physician communication surrounding cognitive concerns. Following results from its 2023 Alzheimer’s Disease Facts and Figures report, the organisation said that a reluctance by the public and doctors to address memory and thinking worries hinders diagnosis and access to potential new treatments. “Providing the best possible care for Alzheimer’s disease requires conversations about memory at the earliest point of concern and a knowledgeable, accessible care team that includes physician specialists to diagnose, monitor disease progression and treat when appropriate,” said Maria Carrillo, chief science officer, Alzheimer’s Association. An accompanying report, The Patient Journey In an Era of New Treatments, also provides new insights from patients and primary care physicians (PCPs) on the current barriers to addressing cognitive concerns. Most focus group participants said their memory and thinking problems would need to have a significant ...
- Source: drugdu
- 145
- March 28, 2023
FDA Grants Breakthrough Therapy Designation to Pfizer’s Investigational Alzheimer’s Disease Treatment

Pfizer, a global pharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational treatment for Alzheimer’s disease, called PF-05217917. This designation is intended to accelerate the development and review of promising drugs that have the potential to address serious or life-threatening conditions. Alzheimer’s disease is a progressive brain disorder that affects millions of people worldwide, causing memory loss and other cognitive impairments. There are currently no approved treatments that can slow or stop the progression of the disease. Pfizer’s PF-05217917 is an antibody that targets the tau protein, which is believed to play a key role in the development and progression of Alzheimer’s disease. The FDA’s decision to grant Breakthrough Therapy designation to PF-05217917 was based on the results of a Phase 2 clinical trial that involved patients with mild to moderate Alzheimer’s disease. The trial showed that ...
- Source: drugdu
- 252
- March 22, 2023
Roche teams up with Lilly to validate Alzheimer’s blood test

March 22 (Reuters) – Roche (ROG.S) and Eli Lilly and Co (LLY.N) are joining forces to develop a blood test for Alzheimer’s disease, and plan to kick off a two-year clinical trial involving hundreds of volunteers with the aim of winning U.S. regulatory approval. The effort, unveiled in a statement on Wednesday, comes as Lilly as well as Eisai (4523.T) and Biogen (BIIB.O) are gearing up to sell drugs aimed at slowing the advance of the mind-robbing illness, but their use will require a diagnosis at earlier disease stages than is the norm today. Roche Holding AG would recruit several hundred volunteers with early signs of dementia over the next 18 to 24 months with trial data potentially ready for a U.S. regulatory filing in 2025, Bruce Jordan, leader of Personalized Healthcare Solutions at Roche Diagnostics, told Reuters. The U.S. Food and Drug Administration has asked Roche to recruit a significant number of patients at primary care facilities ...
- Source: drugdu
- 144
- March 22, 2023
Scientists Develop New Blood Test for Detecting Alzheimer’s Disease

Researchers at Washington University School of Medicine in St. Louis have developed a new blood test that can detect Alzheimer’s disease in its early stages. The test looks for a specific protein called tau, which is known to be a key biomarker of Alzheimer’s. Currently, the most common way to diagnose Alzheimer’s disease is through cognitive testing and brain imaging scans. However, these methods can be costly and invasive. Additionally, by the time symptoms appear, the disease has already caused significant damage to the brain. The new blood test offers a non-invasive and potentially more accessible way to diagnose Alzheimer’s disease early on, when treatments may be more effective. The study, published in the journal Nature Medicine, involved analyzing blood samples from 158 individuals, including healthy adults, individuals with mild cognitive impairment, and individuals with Alzheimer’s disease. The researchers used a technique called mass spectrometry to measure levels ...
- Source: drugdu
- 138
- March 21, 2023
Closing In On The Cause Of Alzheimer’s Disease

The unpredictability of Alzheimer’s disease may be partly caused by changes in star-shaped cells in the brain called astrocytes, find scientists from South Korea. AsianScientist (Dec. 1, 2020) – Despite decades of scientific research, Alzheimer’s disease and its causes still largely remain a mystery. Now, scientists from South Korea have identified a key indicator associated with neurodegeneration in Alzheimer’s. Their findings was published in Nature Neuroscience. Poignantly depicted in Hollywood films like The Notebook and Still Alice, Alzheimer’s disease is a brain disorder that accounts for a majority of cases of dementia, the progressive loss of memory and other cognitive abilities. Over the years, numerous hypotheses regarding the cause of Alzheimer’s have been presented. Perhaps the most prominent is the amyloid hypothesis, which pins the progression of Alzheimer’s on the build-up of beta-amyloid (Aβ) plaques in the brain. These plaques block cell signalling—potentially triggering inflammation and leading to brain cell ...
- Source: drugdu
- 404
- December 2, 2020
Alzheimer's disease
Mouse study tests a novel approach against Alzheimer’s

Source:https://www.medicalnewstoday.com/articles/327291.php#1 Using mouse models of Alzheimer’s disease, researchers have been looking into a new approach to slow down the progression of this neurodegenerative disease — a ketone ester-rich diet.Could a new therapeutic approach help slow down Alzheimer’s disease? Researchers from the NIH investigate.To get the energy it needs to function correctly, the body usually relies on glucose (a simple sugar), which results from the digestion of carbohydrates. When there is not enough glucose to rely on, the body will burn fat instead. This is a process called ketosis, and it is the principle that ketogenic — or keto — diets rely on.Keto diets are typically low in carbohydrates and high in fats, and this imbalance in resources produces ketosis. But there is also another way of inducing ketosis that does not involve making this dietary shift. It involves taking supplements containing ketone ester, which have the same effect. Researchers have ...
- Source: drugdu
- 1,895
- December 13, 2019
Alzheimer's ketosis
Regular daytime nap might lead to Alzheimer disease

Varied research is going on throughout the world in order to find the cause and treatment for Alzheimer’s disease. Scientists from the National Institute on Aging (NIA), Johns Hopkins Medicine and the Bloomberg School have reported that the elders who often feel sleepy during day time are three times more prone to Alzheimer’s disease. These study findings were recently published in the journal named SLEEP. Alzheimer’s disease occurs due to the development of beta-amyloid plaques in brain which results in the changes of nerve structure. The risk of this disease can be reduced by following proper exercise, diet as well as cognitive activities. Recently it was discovered that sleep pattern is also a major risk factor. Improper sleep can develop beta-amyloid protein accumulation in later stage of life. But the reason behind this mechanism is still unknown. The research team came to know the role of sleep by conducting a ...
- Source: drugdu
- 1,273
- September 10, 2018
Breakthrough Device Designation Granted to Digital Intervention for Alzheimer’s

A grave neurodegenerative disease like Alzheimer’s whose cure is still unknown can now be managed with Dthera Sciences’ DTHR-ALZ, a novel digital therapy device which has been bestowed with the prestigious Breakthrough Device designation by the FDA.
- Source: MobiHealthNews
- 1,340
- August 27, 2018
AI Alzheimer's disease FDA New Approvals
Experimental Drug to Treat Alzheimer Disease

The condition of memory loss is termed as Alzheimer’s disease, affecting more than 5 million people and there is still no definite cure. A research team reported that an experimental drug could treat Alzheimer’s disease by slowing down the process of clear thinking and memory.
- Source: NBCNews
- 692
- August 1, 2018
Alzheimer's disease Researches
Monoclonal Antibody Delays Cognitive Decline, Erases Alzheimer’s Plaques in Phase 2 Trial

A phase 2 study on BAN2401, a monoclonal antibody that hits soluble amyloid beta oligomers, showed that it limits cognitive decline in patients with slight cognitive injury or premature Alzheimer’s dementia on two scales and removed brain amyloid in 81% of patients in the trial.
- Source: MDEdge
- 956
- July 30, 2018
Alzheimer's disease Clinical Trials FDA

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.